Merck: Better Times Ahead On Approvals And Outlook

Sundry Photography One of the biggest pharmaceutical stocks by market capitalization, Merck & Co., Inc. (NYSE:MRK) has had a good first quarter at the stock markets in 2024. Its price is up by over 20% after a forgettable 2023 that saw it end the year essentially flat, supported by approvals for its treatments as well as its final quarter (Q4 2023) and full-year 2023 results. Supportive fundamentals might be a necessary condition for a stock’s consistent success in the markets, but they aren’t sufficien ...